Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and complications associated with COVID-19. Capricor is also investigating the field of exosomes and are exploring the potential of exosome-based candidates to treat or prevent a variety of disorders.
Location: United States, California, Los Angeles
Employees: 11-50
Phone: +1 310-358-3200
Total raised: $2M
Founded date: 2005
Investors 2
| Date | Name | Website |
| - | Mayo Clini... | ventures.m... |
| - | Johns Hopk... | ventures.j... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.12.2010 | - | $2M | - |
Mentions in press and media 13
| Date | Title | Description | Source |
| 06.03.2024 | Capricor Therapeutics Presents at 2024 Muscular Dystrophy As... | - | globenewsw... |
| 08.02.2022 | Capricor Therapeutics Relocates to La Jolla | Things are clearly moving in the right direction for Capricor Therapeutics. In November, the company... | sdbj.com/n... |
| 10.11.2021 | Capricor Therapeutics Reports Third Quarter 2021 Financial R... | CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cl... | marketscre... |
| 10.11.2021 | Capricor Therapeutics Reports Third Quarter 2021 Financial R... | Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update CAP... | marketscre... |
| 24.09.2021 | Capricor Therapeutics : Announces Positive Final Data From i... | –Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)–... | marketscre... |
| 24.09.2021 | Capricor Therapeutics : Announces Positive Final Data From i... | Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with D... | marketscre... |
| 12.08.2021 | Capricor Therapeutics : Reports Second Quarter 2021 Financia... | CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol... | marketscre... |
| 12.08.2021 | Capricor Therapeutics : Reports Second Quarter 2021 Financia... | Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update CA... | marketscre... |
| 11.12.2020 | Here's Who is Developing COVID Vaccines in Los Angeles | Los Angeles biotech companies are in a race to create vaccines as the U.S. embarks on the largest pu... | dot.la/cov... |
| 13.11.2020 | Capricor Therapeutics : Reports Third Quarter 2020 Financial... | Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccin... | marketscre... |
Show more